Sleep and Breathing in the General Population - Chemical Stimuli

• Status: Completed
• Trial end date: 2020-02-29
• Target enrollment: 0
• Participant gender: All

Summary

Central sleep apnea (CSA) is a common condition and its treatment remains elusive. The focus of this proposal is to identify the role of the physiologic path involving cortical arousals in CSA by decreasing arousal frequency using the pharmacological agent zolpidem. The goal is to identify the acute effects of administering zolpidem on sleep and respiratory outcomes, and subsequently, its effect on the severity of CSA and propensity to develop CSA. This study will shed light on the mechanisms underlying CSA that involve cortical arousals and will guide future therapeutic interventions for CSA.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wayne State University
• Collaborator: National Institutes of Health (NIH)
• Treatments: Zolpidem

Criteria

Inclusion Criteria:

• Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)>15/hour with CAHI>5/hour, will be included in the experiments.

Exclusion Criteria:

• less than 18 years old

• pregnant or breastfeeding female

• have severe respiratory disease that require to be on oxygen

• recent health event that may affect the ability to participate in the study,

• Body Mass Index (BMI) is >40 kg/m2

• significant insomnia

• mental instability

• recent health event that may affect sleep

• if at any time the principal investigator (PI) identifies that a certain drug is not suitable, or are unable to use the device that is used to treat sleep apnea, will be not be allowed to participate in the study